Éric Vivier, DVM, PhD, is Professor of Immunology at Aix-Marseille University and at the Public Hospital of Marseille.
Prof. Vivier was appointed Scientific Director of Innate Pharma, a biotechnology company dedicated to improving cancer treatment with innovative therapeutic antibodies that exploit the immune system.
Eric Vivier is a graduate of the Ecole Nationale Vétérinaire de Maisons-Alfort and received his PhD in Immunology from the University of Paris XI. He completed his post-doctoral training at Harvard Medical School, then joined Aix-Marseille University as professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993 before becoming its director from 2008 to the end of December 2017.
He is also one of the founders of Marseille-Immunopôle
, an immunology cluster created in 2014 linking fundamental and therapeutic research, innovation and industrial development in the Aix-Marseille region.
Eric Vivier's work focuses on the functioning of Natural killer lymphocytes (NK) and other innate lymphoid cells (ILCs). Professor Vivier has published nearly 300 scientific articles and is on the list of the most cited researchers (https://clarivate.com/hcr/
A laureate of the European Research Council (ERC advanced grants), a member of the Académie Nationale de Médecine and the Institut Universitaire de France, Prof. Vivier has received several awards including those from the Ligue Nationale contre le Cancer (1996, 2004 and 2013) and the European Federation of Immunological Societies (EFIS, 2004).
He is also a Chevalier de la Légion d'Honneur.